AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. Its major products are: Humira (adalimumab) ($9 billion in 2024 revenues, 16% of total revenues), approved to treat autoimmune diseases including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, crohn's disease and ulcerative colitis and administered via injection; Skyrizi (Risankizumab) ($11.7 billion in 2024 revenues, 21% of total revenues), an interleukin-23 (IL-23) inhibitor also used to treat autoimmune diseases; Rinvoq (Upadacitinib) ($6.0 billion in 2023 revenues, 11% of total revenues), used to treat arthritis; and Botox ($6.0 billion in 2024 revenues, 11% of total revenues). Its other major products include Imbruvica (Ibrutinib) to treat cancer ($3.3 billion in 2024 revenues), Vraylar (Cariprazine) to treat schizophrenia and bipolar disorder ($3.3 billion in 2024 revenues), Venclexta (Venetoclax) to treat leukemia and lymphoma ($2.6 billion in 2024 revenues), Mavyret (Glecaprevir/pibrentasvir) to treat Hepatitis C ($1.3 billion in 2024 revenues), and Epkinly (epcoritamab), a blood-cancer therapy developed in partnership with Genmab ($0.1 billion in 2024 revenues). The company is also committed to product development for other treatments of cancer, neurologic diseases, eye care, and cystic fibrosis.: 34 The company's pipeline also includes drug candidates for Parkinson's disease including Vyalev (Foscarbidopa/foslevodopa) and tavapadon.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| ABBV | AbbVie Inc. | 2025-10-16 22:05:26 | 226.65 | -0.22 | -0.1 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABBV | 0001551152 | AbbVie Inc. | US00287Y1091 | FR5LCKFTG8054YNNRU85 | 320375147 | NYSE | 2834 | Pharmaceutical Preparations | 1231 | DE | 1 NORTH WAUKEGAN ROAD | NORTH CHICAGO | IL | 60064 | UNITED STATES | US | (847) 932-7900 | 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL, 60064 | 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL, 60064 | — | Biopharmaceutical | 2012-04-10 | Robert Michael | 55,000 | http://abbvie.com | 300,173,162,268 | 1,837,290,114 | 1,766,558,253 | AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. Its major products are: Humira (adalimumab) ($9 billion in 2024 revenues, 16% of total revenues), approved to treat autoimmune diseases including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, crohn's disease and ulcerative colitis and administered via injection; Skyrizi (Risankizumab) ($11.7 billion in 2024 revenues, 21% of total revenues), an interleukin-23 (IL-23) inhibitor also used to treat autoimmune diseases; Rinvoq (Upadacitinib) ($6.0 billion in 2023 revenues, 11% of total revenues), used to treat arthritis; and Botox ($6.0 billion in 2024 revenues, 11% of total revenues). Its other major products include Imbruvica (Ibrutinib) to treat cancer ($3.3 billion in 2024 revenues), Vraylar (Cariprazine) to treat schizophrenia and bipolar disorder ($3.3 billion in 2024 revenues), Venclexta (Venetoclax) to treat leukemia and lymphoma ($2.6 billion in 2024 revenues), Mavyret (Glecaprevir/pibrentasvir) to treat Hepatitis C ($1.3 billion in 2024 revenues), and Epkinly (epcoritamab), a blood-cancer therapy developed in partnership with Genmab ($0.1 billion in 2024 revenues). The company is also committed to product development for other treatments of cancer, neurologic diseases, eye care, and cystic fibrosis.: 34 The company's pipeline also includes drug candidates for Parkinson's disease including Vyalev (Foscarbidopa/foslevodopa) and tavapadon. | 2025-10-10 19:00:31 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 300,173,162,268 | 64,543,469,353 | 27.3919 | 1,765,354,859 | -1,118,500 | -0.0633 |
| 2023 | 235,629,692,915 | -32,622,905,396 | -12.1613 | 1,766,473,359 | -2,926,612 | -0.1654 |
| 2022 | 268,252,598,311 | 71,006,689,094 | 35.9991 | 1,769,399,971 | 646,142 | 0.0365 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Laura J. Schumacher | Chief Legal Officer, Vice Chairman | 2019 | 1,176,538 | 0 | 3,400,155 | 2,400,000 | 727,225 | 15,142,787 |
| Carlos Alban | Chief Commercial Officer, Vice Chairman | 2019 | 1,176,538 | 0 | 3,091,161 | 2,400,000 | 500,283 | 14,406,090 |
| Richard A. Gonzalez | Chief Executive Officer, Chairman Of The Board | 2019 | 1,650,000 | 0 | 8,887,088 | 4,335,000 | 1,125,537 | 21,610,598 |
| Robert A. Michael | Chief Financial Officer, Executive Vice President | 2019 | 906,865 | 0 | 2,704,766 | 1,800,000 | 55,471 | 8,772,853 |
| Michael E. Severino | President, Vice Chairman | 2019 | 1,330,000 | 0 | 3,199,248 | 2,400,000 | 245,467 | 9,508,448 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 55,000 |
| 2023 | 50,000 |
| 2022 | 50,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 56,334,000,000 | 54,318,000,000 | 58,054,000,000 |
| Cost Of Revenue | 16,904,000,000 | 20,415,000,000 | 17,414,000,000 |
| Gross Profit | 10,706,000,000 | 8,597,000,000 | 10,951,000,000 |
| Research And Development Expenses | 12,791,000,000 | 7,675,000,000 | 6,510,000,000 |
| General And Administrative Expenses | 14,752,000,000 | 12,872,000,000 | 15,260,000,000 |
| Operating Expenses | 47,197,000,000 | 41,561,000,000 | 39,937,000,000 |
| Operating Income | 9,137,000,000 | 12,757,000,000 | 18,117,000,000 |
| Net Income | 4,278,000,000 | 4,863,000,000 | 11,836,000,000 |
| Earnings Per Share Basic | 2.4 | 2.73 | 6.65 |
| Earnings Per Share Diluted | 2.39 | 2.72 | 6.63 |
| Weighted Average Shares Outstanding Basic | 1,769,000,000 | 1,768,000,000 | 1,771,000,000 |
| Weighted Average Shares Outstanding Diluted | 1,773,000,000 | 1,773,000,000 | 1,778,000,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 5,524,000,000 | 12,814,000,000 | 9,201,000,000 |
| Marketable Securities Current | 31,000,000 | 2,000,000 | 28,000,000 |
| Accounts Receivable | 10,919,000,000 | 11,155,000,000 | 11,254,000,000 |
| Inventories | 4,181,000,000 | 4,099,000,000 | 3,579,000,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 25,582,000,000 | 33,002,000,000 | 28,463,000,000 |
| Marketable Securities Non Current | 279,000,000 | 304,000,000 | 241,000,000 |
| Property Plant And Equipment | 5,134,000,000 | 4,989,000,000 | 4,935,000,000 |
| Other Assets Non Current | 9,142,000,000 | 8,513,000,000 | 5,571,000,000 |
| Total Assets Non Current | 5,134,000,000 | 4,989,000,000 | 4,935,000,000 |
| Total Assets | 135,161,000,000 | 134,711,000,000 | 138,805,000,000 |
| Accounts Payable | 2,945,000,000 | 3,688,000,000 | 2,934,000,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | 6,804,000,000 | 0 | 1,000,000 |
| Other Liabilities Current | — | — | — |
| Total Liabilities Current | 38,749,000,000 | 37,841,000,000 | 29,538,000,000 |
| Long Term Debt | 66,841,000,000 | 59,245,000,000 | 63,128,000,000 |
| Other Liabilities Non Current | 30,129,000,000 | 32,327,000,000 | 30,655,000,000 |
| Total Liabilities Non Current | — | — | — |
| Total Liabilities | — | — | — |
| Common Stock | 18,000,000 | 18,000,000 | 18,000,000 |
| Retained Earnings | -7,900,000,000 | -1,000,000,000 | 4,784,000,000 |
| Accumulated Other Comprehensive Income | -1,925,000,000 | -2,305,000,000 | -2,199,000,000 |
| Total Shareholders Equity | 3,325,000,000 | 10,360,000,000 | 17,254,000,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 764,000,000 | 752,000,000 | 778,000,000 |
| Share Based Compensation Expense | 911,000,000 | 747,000,000 | 671,000,000 |
| Other Non Cash Income Expense | 63,000,000 | 225,000,000 | 150,000,000 |
| Change In Accounts Receivable | -207,000,000 | -66,000,000 | 1,455,000,000 |
| Change In Inventories | 319,000,000 | 417,000,000 | 686,000,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 177,000,000 | 3,840,000,000 | 1,605,000,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | 18,806,000,000 | 22,839,000,000 | 24,943,000,000 |
| Purchases Of Marketable Securities | 73,000,000 | 77,000,000 | 1,438,000,000 |
| Sales Of Marketable Securities | 555,000,000 | 55,000,000 | 1,530,000,000 |
| Acquisition Of Property Plant And Equipment | 974,000,000 | 777,000,000 | 695,000,000 |
| Acquisition Of Business | 17,493,000,000 | 0 | 255,000,000 |
| Other Investing Activities | -189,000,000 | -13,000,000 | -774,000,000 |
| Cash From Investing Activities | -20,820,000,000 | -2,009,000,000 | -623,000,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | 11,178,000,000 | 10,647,000,000 | 10,179,000,000 |
| Issuance Of Common Stock | — | — | — |
| Repurchase Of Common Stock | 1,708,000,000 | 1,972,000,000 | 1,487,000,000 |
| Issuance Of Long Term Debt | 16,963,000,000 | — | 2,000,000,000 |
| Repayment Of Long Term Debt | 9,613,000,000 | 4,149,000,000 | 14,433,000,000 |
| Other Financing Activities | 57,000,000 | 48,000,000 | 30,000,000 |
| Cash From Financing Activities | -5,211,000,000 | -17,222,000,000 | -24,803,000,000 |
| Change In Cash | -7,290,000,000 | 3,613,000,000 | -545,000,000 |
| Cash At End Of Period | 5,524,000,000 | 12,814,000,000 | 9,201,000,000 |
| Income Taxes Paid | 4,064,000,000 | 4,702,000,000 | 2,988,000,000 |
| Interest Paid | 2,811,000,000 | 2,469,000,000 | 2,546,000,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | 2.4 | 2.73 | 6.65 |
| Price To Earnings Ratio | 74.0417 | 56.7656 | 24.3023 |
| Earnings Growth Rate | -12.0879 | -58.9474 | 2.6235 |
| Price Earnings To Growth Ratio | -6.1253 | -0.963 | 9.2634 |
| Book Value Per Share | 54.5008 | 54.7907 | 61.6979 |
| Price To Book Ratio | 3.2605 | 2.8284 | 2.6194 |
| Ebitda | 11,914,000,000 | 12,541,000,000 | 17,832,000,000 |
| Enterprise Value | 382,472,300,000 | 320,417,960,000 | 340,139,310,000 |
| Dividend Yield | 0.0356 | 0.0389 | 0.0356 |
| Dividend Payout Ratio | 2.6129 | 2.1894 | 0.86 |
| Debt To Equity Ratio | 22.1489 | 5.7186 | 3.6588 |
| Capital Expenditures | 909,000,000 | 806,000,000 | 603,000,000 |
| Free Cash Flow | 17,897,000,000 | 22,033,000,000 | 24,340,000,000 |
| Return On Equity | 1.2866 | 0.4694 | 0.686 |
| One Year Beta | 0.2488 | 0.2038 | 0.3507 |
| Three Year Beta | 0.2989 | 0.3615 | 0.593 |
| Five Year Beta | 0.5358 | 0.5863 | 0.6811 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| RAPP EDWARD J | Director | 2025-09-30 | 145 | A | 28,152 |
| Alpern Robert J | Director | 2025-09-30 | 33 | A | 10,151 |
| Quaggin Susan E | Director | 2025-09-30 | 67 | A | 634 |
| SALEKI-GERHARDT AZITA | EVP, CHIEF OPERATIONS OFFICER | 2025-08-12 | 42,370 | A | 219,662 |
| SALEKI-GERHARDT AZITA | EVP, CHIEF OPERATIONS OFFICER | 2025-08-12 | 42,370 | D | 177,292 |
| Name Of Reporting Person | Type Of Reporting Person | Report Date | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| John Boozman | Senator | 2025-09-12 | Sale (Partial) | 2025-08-22 | Joint | $1,001 - $15,000 |
| John Boozman | Senator | 2025-09-12 | Sale (Partial) | 2025-08-11 | Joint | $1,001 - $15,000 |
| Thomas H Tuberville | Senator | 2024-05-15 | Purchase | 2024-04-03 | Joint | $1,001 - $15,000 |
| Thomas H Tuberville | Senator | 2024-02-14 | Sale (Full) | 2024-01-19 | Joint | $1,001 - $15,000 |
| Thomas H Tuberville | Senator | 2023-12-15 | Sale (Full) | 2023-11-20 | Joint | $1,001 - $15,000 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Julie Johnson | 2025-09-11 | TX32 | Sale (Partial) | 2025-08-14 | Joint | $1,001 - $15,000 |
| Ritchie John Torres | 2025-08-20 | NY15 | Sale | 2025-07-11 | — | $1,001 - $15,000 |
| Ritchie John Torres | 2025-08-20 | NY15 | Purchase | 2024-09-26 | — | $1,001 - $15,000 |
| Lisa McClain | 2025-08-13 | MI09 | Purchase | 2025-07-22 | Spouse | $1,001 - $15,000 |
| Lisa McClain | 2025-08-13 | MI09 | Purchase | 2025-06-17 | Spouse | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Bill Few Associates, Inc. | 2025-09-30 | 7,890,381 | 34,078 | 231.5389 |
| LOCKERMAN FINANCIAL GROUP, INC. | 2025-09-30 | 318,368 | 1,375 | 231.5404 |
| WILLNER & HELLER, LLC | 2025-09-30 | 1,758,667 | 7,596 | 231.5254 |
| Carnegie Investment Counsel | 2025-09-30 | 32,229,025 | 139,194 | 231.5403 |
| 180 WEALTH ADVISORS, LLC | 2025-09-30 | 621,851 | 2,686 | 231.5156 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| TRUST FOR PROFESSIONAL MANAGERS | 2025-08-31 | Dearborn Partners Rising Dividend Fund - Class I Shares | DRDIX | 65,100 | 13,697,040 | 2.1697 |
| TRUST FOR PROFESSIONAL MANAGERS | 2025-08-31 | Dearborn Partners Rising Dividend Fund - Class C Shares | DRDCX | 65,100 | 13,697,040 | 2.1697 |
| TRUST FOR PROFESSIONAL MANAGERS | 2025-08-31 | Dearborn Partners Rising Dividend Fund - Class A Shares | DRDAX | 65,100 | 13,697,040 | 2.1697 |
| ETF Series Solutions | 2025-07-31 | Aptus Large Cap Enhanced Yield ETF | DUBS | 7,871 | 1,487,776.42 | 0.6222 |
| ETF Series Solutions | 2025-07-31 | Aptus Large Cap Upside ETF | UPSD | 5,336 | 1,008,610.72 | 1.2225 |